Differences in Uptravi maintenance doses had no impact on the risk of hospitalization among adults with PAH, a claims ...

Normally, these nasty effects are kept in check by another chemical called prostacyclin. But prostacyclin is made, in part, with the help of Cox-2 enzymes -- the enzymes that drugs like Celebrex ...

Investigators say more research is warranted to optimize management of patients with pulmonary arterial hypertension (PAH) ...

Can eating fat be good for us? Some fatty acid molecules actually play a crucial role in maintaining our health and cellular functions. By the early twentieth century, scientists and doctors ...

Future Cardiol. 2013;9(3):335-349. Research into prostacyclin analogs for the treatment of WHO Group 2 PH has been limited, likely due to the early termination of the FIRST trial. [55] This study ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against other best ...

Most participants were receiving either three (61%) or two (35%) background drugs for PAH, and 40% were receiving prostacyclin infusions. The mean time from PAH diagnosis was 8.8 years.

The clinical significance and frequency of adverse events with tNSAIDs in the lower GI tract have been increasingly reported, but are much more poorly characterized than those from the upper GI ...

They also produce signaling molecules like nitric oxide and prostacyclin to maintain vascular balance. However, EC ...

United Therapeutics is also in search of an effective medicine with trepostinil, a prostacyclin mimetic, currently in phase 3 development for IPF. As is Bristol-Myers Squibb, recently announcing ...

This growth is largely attributed to the successful performance of its key products, such as Tyvaso, the leading prostacyclin treatment in the US. TD Cowen has maintained a positive outlook on ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five presentations and one poster across its commercial and development portfolio will be presented ...